Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
November 03 2023 - 9:00AM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third
quarter 2023 financial results on Wednesday, November 8th, 2023
before the markets open. Management will conduct a conference call
and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss
the financial results and to provide a business update.
Dial-in InformationU.S. Dial-in
Number: (888) 317-6003International Dial-in Number: (412)
317-6061Conference ID: 2598226
Replay InformationU.S. Dial-in
Number: (877) 344-7529Replay International Dial-in Number: (412)
317-0088Conference ID: 5587137
The dial-in replay will be available for 7 days
following the call. An audio webcast will be available online at
www.lexpharma.com/events, with a webcast replay accessible for 14
days after the call.
About Lexicon
Pharmaceuticals
Lexicon is a biopharmaceutical company with a
mission of pioneering medicines that transform patients’ lives.
Through its Genome5000™ program, Lexicon scientists studied the
role and function of nearly 5,000 genes and identified more than
100 protein targets with significant therapeutic potential in a
range of diseases. Through the precise targeting of these proteins,
Lexicon is pioneering the discovery and development of innovative
medicines to safely and effectively treat disease. Lexicon has
advanced multiple medicines to market and has a pipeline of
promising drug candidates in discovery and clinical and preclinical
development in heart failure, neuropathic pain, diabetes and
metabolism and other indications. For additional information,
please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s financial
position and long-term outlook on its business, including the
commercialization of its approved products and the clinical
development of, regulatory filings for, and potential therapeutic
and commercial potential of its other drug candidates. In addition,
this press release also contains forward looking statements
relating to Lexicon’s growth and future operating results,
discovery, development and commercialization of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management’s current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including Lexicon’s ability to meet its
capital requirements, successfully commercialize its approved
products, successfully conduct preclinical and clinical development
and obtain necessary regulatory approvals of its other drug
candidates on its anticipated timelines, achieve its operational
objectives, obtain patent protection for its discoveries and
establish strategic alliances, as well as additional factors
relating to manufacturing, intellectual property rights, and the
therapeutic or commercial value of its approved products and other
drug candidates. Any of these risks, uncertainties and other
factors may cause Lexicon’s actual results to be materially
different from any future results expressed or implied by such
forward-looking statements. Information identifying such important
factors is contained under “Risk Factors” in Lexicon’s annual
report on Form 10-K for the year ended December 31, 2022, as filed
with the Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Investor Inquiries:
Lexicon Investor RelationsLexicon
Pharmaceuticals, Inc.lexinvest@lexpharma.com
For Media Inquiries:
Alina CocuzzaLexicon Pharmaceuticals,
Inc.acocuzza@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024